In order to get to Phase 3 don't you need approval from the FDA? Don't they review Phase 2 results and either give you the green light which is always super positive or they say no we don't think your phase 2 has shown enough promise?
I don't know the answer and was hoping someone could clarify for me?
Without knowing the results of the K p1 it is too early to know which of the options Leo will go for. If K shows efficacy in P! for one or more types of tumors/cancers then the range of options expands nicely.
Kind of amazing that we have come this far without massive dilution. If the SP is high enough Leo may do an equity offering, if not then I look for a deal with one of the compounds. My own guess is P would be the first choice since it is targeting a single disease. B & K are potential platforms for so many possible targets I don't think Menon would let go of either this early.. BWTHDIK? Perhaps this will be discussed at R&R.
I am betting Leo and Menon will do right by the retail shareholders.
AND, I think it is still a possibility that K will have the results that will allow it to advance directly to a P3 trial for at least one tumor type. Just have to sit tight and see what develops.
News 
Market Data 
Discover 
AI
